US Patent Issued to Alnylam Pharmaceuticals on July 14 for "Complement component C3 iRNA compositions and methods of use thereof for treating or preventing complement component C3-associated diseases" (Massachusetts Inventors)

ALEXANDRIA, Va., July 14 -- United States Patent no. 12,680,099, issued on July 14, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Complement component C3 iRNA compositions and methods of use thereof for treating or preventing complement component C3-associated diseases" was invented by Mark Keating (Weston, Mass.) and James D. McIninch (Burlington, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the complement component C3 gene and methods of using such iRNA agents for treating or preventing C3-associated ocular diseases or C3-associated neurodegenerative diseases."

The patent was filed on Sep...